Dr. Miron on Kidney Cancer Updates, Molecular Alterations in Intraductal Carcinoma of the Prostate

By Benjamin Miron, MD - Last Updated: June 16, 2023

Benjamin Miron, MD, Fox Chase Cancer Center, comments on whether the long-term data from key kidney cancer trials (eg, CLEAR and KEYNOTE-426) confirm survival benefit of certain therapies, as well as provides an overview of his study on clinical implications of molecular alterations in intraductal carcinoma of the prostate.

View more ASCO 2023 videos.

Real-world Association of Tumor-Informed MRD With Clinical Outcomes for MIBC

Ajitha Kommalapati, MDASCO 2023 | August 15, 2023

Dr. Kommalapati shares her thoughts on the association between tumor-informed MRD and clinical outcomes for MIBC.

Drs. Gupta, Koshkin on EV-103 Cohort K Results and Toxicities

Shilpa Gupta, MDASCO 2023 | August 4, 2023

Drs. Shilpa Gupta and Vadim Koshkin continue on the EV-103 trial with reference to outcomes and toxicities in cohort K.

Drs. Gupta, Koshkin on EV-103 Design and Long-term Cohort A Results for Patients With aUC

Shilpa Gupta, MDASCO 2023 | August 31, 2023

Drs. Shilpa Gupta and Vadim Koshkin discuss the EV-103 trial and data, including long-term results for cohort A.

Biomarkers of Response to SG and EV in Advanced Urothelial Carcinoma: Analysis of the UNITE Study

Tanya JindalASCO 2023 | July 28, 2023

Tanya Jindal expands upon the UNITE study findings relative to biomarkers of response for SG and EV for advanced UC.

Dr. Thomas Hutson on Long-Term Durable Response After 4 Years Follow-Up in the CLEAR Study

Thomas Hutson, DO, PharmD, FACPASCO 2023 | July 17, 2023

Dr. Hutson details the latest 4-year CLEAR data for patients who received 1L lenvatinib plus pembrolizumab for advanced RCC.

Dr. Miron on Kidney Cancer Updates, Molecular Alterations in Intraductal Carcinoma of the Prostate

Related Posts